Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil

Abstract

Background There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann–Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03–2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19–6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31–3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46–0.98). Conclusion Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR – 9KTWX6).

Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort

“…Multiple studies across the globe have failed to demonstrate a significant reduction in the SARS-CoV-2 infection in SLE patients who are on long-term HCQ therapy. 15 – 17 Furthermore, in a large population-based survey involving more than 26,000 patients of lupus in the UK, HCQ did not influence the mortality due to COVID-19. 18 …”

Evaluation of favipiravir in the treatment of COVID-19 based on the real-world

“…As the drug most frequently appearing in the control group of included studies, HCQ was initially applied to the treatment of COVID-19 because of its potential benefit of attenuating the cytokine storm observed in moderate or severe COVID-19 forms and mitigating unfavorable outcomes, however, there is controversy regarding its efficacy and safety in the treatment of patients with COVID-19 [ 49 ]. Several studies have demonstrated that HCQ and azithromycin, alone or in combination, prolong the QTc interval, which can easily lead to myocarditis, a very common complication after infection with SARS-CoV-2 [ 50–54 ].…”

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

“…abatacept), IL-6 inhibitors, and non-steroidal anti-inflammatory drugs presented a similar occurrence and outcome of COVID-19 as occurred with the controls. Regarding hydroxychloroquine, the risk of adverse reactions increases when doses are higher than usual in hospitalized COVID-19 patients [ 102 ]. Regarding Jak-inhibitors, conflicting results have been reported, which may be related to the dual effect of Jak-inhibitors in controlling both the innate immune response and the cytokine storm associated with severe COVID-19 [ 103 ].…”